Member Info for alextak

Gap Up 🚀..soon

https://www.marketbeat.com/stocks/LON/FUM/competitors-and-alternatives/

The article highlights the potential benefits of AFX001, including its ability to control autoimmune responses and its potential to treat a wide range of autoimmune diseases.

https://www.hkn24.com/news/articleView.html?idxno=341571

Although Avacta is not directly mentioned in the article, the research conducted under this programme is relevant to Avacta's work in developing novel cancer therapies. Specifically, the identification of biomarkers that predict patient response to immunotherapy could potentially help Avacta in developing personalized treatments and optimizing the effectiveness of their therapies. Moreover, understanding the factors that contribute to immunotherapy success or toxicity could also inform Avacta's research and development efforts, ultimately benefiting patients who rely on these treatments.

https://www.ddw-online.com/uk-wide-programme-to-boost-success-of-immunotherapy-31888-202410/

Hmmm...

if the share price reaches £6, I'd sell a slice and consider quitting my job next June.

Just chillin' all summer long. 😎⛱️🍹

THE SEX WAS SO GOOD EVEN THE NEIGHBORS HAD A CIGARETTE

Unfortunately you wright .

AI;The price of industrial-grade diamonds from Zimbabwe's Chiadzwa diamond fields can vary widely depending on factors such as market demand, diamond quality, and the specific agreements between buyers and sellers. Based on some reports, the average price for these diamonds can range from $20 to $45 per carat. However, it's important to keep in mind that the diamond industry is complex and prices can fluctuate significantly. Additionally, the diamonds from this region have been the subject of controversy due to legal disputes, forced labor allegations, and other issues.

Another few hundred percent rise and I might be brave enough to check my holdings here again. 🙏😅💎💎

AI:

Given the specific context of 129,400 carats of diamonds from Zimbabwe's Chiadzwa diamond fields, it's important to consider the quality and market factors specific to these diamonds. According to some reports, the diamonds from this region are below average in quality, and they could potentially fetch a lower price per carat compared to higher quality diamonds.

Using a rough estimate of $300 per carat, as suggested for diamonds from this area, the parcel could be worth approximately $38.82 million. However, keep in mind that actual prices could vary significantly depending on factors such as global demand, diamond quality, and market conditions at the time of sale.

I know this has been discussed earlier, but approximately how much money are we talking about when we say 129,400 carats of diamonds?

Https://www.linkedin.com/company/ondoplc

100 million for a preclinical?

https://www.pharmaceutical-business-review.com/news/astrazeneca-license-cspc-therapy/

What's wrong, troll boy? Did your mommy not love you?

Https://x.com/RAH00084/status/1842854224721289446

Scalable (potentially many dozens of existing oncology therapeutics could be enhanced by the pre|CISION substrate), and that its clinical development pathway is both shorter and lower risk than most other novel drugs in targeted oncology (no requirement for Phase 3 trials; and the efficacy of new drugs is not being tested (at least from scratch) in pre|CISION prodrug clinical trials). We believe that these three fundamental advantages over other targeted oncology platforms place pre|CISION in a truly unique position. Accordingly, we think that in the event of pre|CISION proving effective in man, the platform could earn a premium valuation rating over its peers.

Cells (i.e. an immunotherapy). At the time of the acquisition announcement, magrolimab was in the middle of a Phase 1b clinical trial. - Merck acquires VelosBio for $2.8 billion 13 In November 2020, Merck announced that it would be acquiring VelosBio for $2.75 billion in cash. At the time, VelosBio’s lead investigational candidate – VLS-101, an antibody-drug conjugate targeting ROR1 – was being evaluated in Phase 1 and Phase 2 clinical trials for the treatment of patients with haematological malignancies and solid tumours, respectively. [The P2 trial had commenced only in October 2020.] - Boehringer Ingelheim acquires NBE Therapeutics for €1.2 billion 14 In December 2020, Boehringer Ingelheim announced that it would be acquiring NBE-Therapeutics for €1.18 billion. NBE-Therapeutics’s lead compound, an antibody-drug conjugate named NBE-002, was in the middle of a Phase 1 clinical trial. - Pfizer acquires Trillium Therapeutics for $2.3 billion 15 In August 2021, Pfizer agreed to acquire Trillium Therapeutics for $2.26 billion in cash. Trillium had two lead candidates – both next-generation, investigational immuno-therapeutics for haematological malignancies – in Phase 1b/2 trials. The target launch date for both drugs (assuming successful clinical development) is 2026. Phase 3 acquisitions: - Gilead acquires Immunomedics for $21 billion 16 In September 2020, Gilead agreed to acquire NASDAQ-listed Immunomedics for $21 billion in cash. Immunomedics’ lead product is a first-in-class antibody-drug conjugate, branded Trodelvy. Following a successful Phase 3 trial, Immunomedics had been granted FDA approval in April 2020 for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. At the time of the acquisition, Immunomedics had only generated sales of $20m from Trodelvy (it had, after all, only just gone on market). The deal valued Immunomedics at over 5x peak sales of $4 billion, which was estimated to be reached in 2029. - GlaxoSmithKline acquires Sierra Oncology for $1.9 billion 17 In April 2022, GSK reached an agreement to acquire NASDAQ-listed Sierra Oncology for $1.9 billion in cash. Sierra’s lead candidate, momelotinib, is a JAK inhibitor for the treatment of myelofibrosis (an uncommon type of bone marrow cancer). It announced positive results from its Phase 3 trial in January of this year, and is awaiting FDA approval. “ 21 [For a comprehensive list of billion dollar dealmaking in the oncology world in 2020 and 2021 – including both licensing deals and acquisitions – please see the footnote below.18] When considering how Avacta may be valued against its peers, it is vital to keep in mind that pre|CISION is a platform technology. Not only that, but it is a delivery platform technology, that happens to be highly agnostic with regards to the classes of drug it could be primed to modify and deliver. This means that it is immensely sca

“Rather, we will simply highlight a selection of recent transactions in the targeted cancer therapy space (including immunotherapies and antibody-drug conjugates (‘ADC’)), so as to provide some insight into the value attributed to these classes of drugs by Big Pharma, even at relatively early stages of clinical development. Collaborations: - Genentech and Bicycle Therapeutics collaboration (up to $1.7 billion) 9 In February 2020, Genentech (a member of Roche Group) and Bicycle Therapeutics announced an exclusive strategic collaboration to develop and commercialise Bicycle®-based targeted immunotherapies against multiple targets. The collaboration involves the discovery and pre-clinical development of novel therapies, and does not include any candidate from Bicycle’s existing and wholly owned pipeline. Bicycle received a $30 million upfront payment. The upfront payment and potential discovery, development, regulatory and commercial-based milestone payments could total up to $1.7 billion. - AstraZeneca and Daiichi Sankyo collaboration (up to $6 billion) 10 In July 2020, AstraZeneca and Daiichi Sankyo Company entered into a new global development and commercialisation agreement for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (‘TROP2’)-directed antibody-drug conjugate. Using Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062 is designed to deliver chemotherapy selectively to cancer cells and to reduce systemic exposure. AstraZeneca would pay Daiichi Sankyo an upfront fee of $1bn; and pay additional conditional amounts of up to $1bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones. At the time of the agreement, Daiichi Sankyo had only just commenced enrolling patients for a Phase 1 trial. Neither safety nor efficacy for DS-1062 had been established. - Bristol Myers Squibb and Eisai collaboration (up to $3.1 billion) 11 In June 2021, BMS and Eisai entered into a global strategic collaboration agreement for the co-development and co-commercialisation of Eisai’s first antibody-drug conjugate, MORAb-202. The ADC combines Eisai’s in-house developed anti-folate receptor alpha (FRa) antibody, and Eisai’s anticancer agent eribulin, using an enzyme cleavable linker. At the time, MORAb-202 was being tested in two studies: a Phase 1 study in Japan and a Phase 1/2 study in the US. Under the financial terms of the agreement, BMS paid $650m to Eisai ($200m of which was to cover Eisai’s R&D expenses). Eisai is also entitled to receive up to $2.45bn in potential future development, regulatory, and commercial milestones”

“Phase 1 / 2 acquisitions: - Gilead acquires Forty Seven for $4.9 billion 12 In March 2020, Gilead agreed to acquire Forty Seven for $4.9 billion in cash. Forty Seven’s investigational lead product candidate, magrolimab, is a monoclonal antibody therapy targeting the CD47 protein overexpressed on the surface of many types of cancer

Https://ukinvestormagazine.co.uk/avacta-group-exploring-nasdaq-dual-listing-and-divesting-its-diagnostics-division-analyst-has-188p-valuation-shares-now-45-5p/

With or without Combination therapy?

(It's getting a little complicated 🤔

"Exploration of combinations and sequences of

administration of anticancer drugs to improve

outcomes

Treatment with targeted anticancer drugs used as

single agents for metastatic cancers have resulted

in prolonged survival, but not cure. Understanding

and overcoming drug resistance to targeted therapy

is critical to improving outcomes or these patients.

Much of the focus on finding biomarkers of sensitivity

and resistance to targeted agents have focused on

genomic biomarkers. Mechanisms of resistance to

targeted therapy often includes redundancies in signal

transduction pathways and this could be overcome by

combination therapy.

Conversely, treatment with chemotherapeutic agents

are often used in combination regimens. Here the

main aim is to cause maximal damage to cancer

cells using drugs that do not have overlapping side

effects. These lead to effective but toxic schedules.

The selection pressure of chemotherapeutic drugs

cause evolution of cancer cells into drug resistant

and sensitive populations leading to tumour

heterogeneity. Understanding the dynamics of growth

of these clonal populations in the laboratory can open

opportunities to use chemotherapy as single agents in

specific sequences rather than in combinations with

an aim to achieve similar efficacy but less side effects.

Preclinical experiments and methods of clinical

translation will be presented"

Professor Udai Banerji

(btw,you could meet Professors Udai Banerji and Ruth Plummer at the International Charles Heidelberger Symposium on Cancer Research in Belfast next week)

Https://toukankahmoonsuckmydick/.com

Not sure if this has been posted. Apologies if it has.

We are a next-generation cell gene therapy development company jointly established by a large pharmaceutical company and British Avacta Life Science. We are developing next-generation cell gene therapy optimized for immune regulation by converging Affimer platform technology to enhance immune regulation function based on mesenchymal stem cell platform technology. We are currently preparing for phase 1 clinical trials with the US FDA, and are looking for a Chief Scientific Officer (CSO) who can oversee this research and development process and establish strategies.

Main tasks

• Main duties include overseeing the development of cell and gene therapy products, establishing innovative scientific strategies, building collaborative relationships with academia and industry, and effectively producing research results in compliance with regulatory requirements. - Overseeing research and development (R&D) and recruiting, training, and managing scientific talent to maximize the team's performance - Establishing the company's scientific strategy and setting R&D goals and directions to promote sustainable innovation - Overseeing clinical development strategies, including preparation and execution of Phase 1 clinical trials, and leading collaboration with the FDA and other regulatory agencies - Establishing collaborative relationships with academia, industry, and other research institutions to expand joint research and development opportunities - Managing the R&D budget and optimizing resource allocation to increase project efficiency - Effectively communicating research results to internal and external stakeholders and representing the company's scientific vision - Identifying future growth engines and establishing new business strategies

https://career.rememberapp.co.kr/job/posting/183251?campaign=google_jobs_apply&channel=google_jobs_apply